Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b continuation study of TAK-755 in severe congenital TTP
jRCT2031220348Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- Sep 2021
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
01
Overview
Phase 3, open-label trial of Apadamtase alfa in Upshaw-Schulman syndrome (USS) (2 cohorts), sponsored by Takeda. Primary endpoints: Incidence of related treatment-emergent adverse events and related serious adverse events and Safety parameters (vital signs, clinical chemistry, hematology). Started Sep 2021; status: active, not recruiting.
02
Drugs
Apadamtase alfa
03
Conditions
Upshaw-Schulman syndrome (USS)
Beyond the preview
Go deeper on jRCT2031220348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220348.